Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

Strasser, S.; Chan, H.; Ahn, S.; Chuang, W.; Hui, A.; Tabak, F.; Mehta, R.; Petersen, J.; Lee, C.; Ma, X.; Caruntu, F.; Tak, W.; Elkhashab, M.; Lin, L.; Dinh, P.; Martins, E.; Charuworn, P.; Mchutchison, J.; Subramanian, G. M.; Lim, S.; Foster, G.; Fung, S.; Morano, L.; Samuel, D.; Agarwal, K.; Idilman, R.; Buti, M.; Gaeta, G.; Papatheodoridis, G.; Flisiak, R.; Marcellin, P.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

Journal article published in 2015 by S. Strasser, H. Chan, S. Ahn, W. Chuang, A. Hui, F. Tabak, R. Mehta, J. Petersen, C. Lee, X. Ma, F. Caruntu, W. Tak, M. Elkhashab, L. Lin, P. Dinh and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload